Published on 1 December 2022
Description:
Neurology, Rare Diseases, Cardiovascular and Metabolic Health
37 articles from this collection:
Pharmafile
Therapeutic areas in focus Volume 74 Autumn 2022: Welcome to issue 74 of Pharmafile! This issue covers topics from neurology to rare diseases and cardiovascular and metabolic health, as well as a brand new news section
PrimeVigilance
PrimeVigilance: Full Global Pharmacovigilance Services
Contents
Therapeutic Areas in Focus: Issue 74 covers topics such as neurology, rare diseases and cardiovascular and metabolic health, as well as debuting a news section.
Editor’s letter
Read this issue's editor's letter summarising the year's developments in the pharma sphere
Samedan Ltd
Samedan Ltd: Fast, Effective Insight
Merger planned between Bio-Rad and Qiagen
Bio-Rad and Qiagen plan to merge in a deal potentially worth over $10bn
Aptar Pharma completes first phase of global expansion
Aptar Pharma completes first stage of its global expansion programme, costing approximately $180m
Johnson & Johnson to buy Abiomed for $17bn
Johnson & Johnson is planning to acquire Abiomed for $17bn
Norstella and Citeline merge to create $5bn pharma tech firm
Merger completed between Norstella and Citeline to create $5bn pharma tech firm
Oxford biotech purchased by AbbVie for $255m
DJS Antibodies acquired by AbbVie for $255m
Gilead and MacroGenics partner for bispecific antibody development
Gilead Sciences and Macrogenics partner for bispecific antibody development
AI device to treat chronic pain approved by FDA
FDA approves Nevro Corporation's new AI device to treat chronic pain
EC approves CAR T cell therapy for B cell lymphoma
CAR T cell therapy for B cell lymphoma approved by European Commission
AstraZeneca’s liver cancer treatment gets FDA approval
FDA approves AstraZeneca's liver cancer treatment
FDA clears GSK’s Boostrix for use in pregnancy
FDA approves GSK's whooping cough vaccine, Boostrix, for use in pregnant patients
Furosemide approved by FDA for patients with chronic heart failure
FDA approves Furosemide to treat patients with chronic heart failure
Controversial ALS drug approved by FDA
New but controversial ALS drug, Relyviro, approved by FDA
Merck under official investigation in France
Pharma company, Merck, is under official investigation in France
FDA announces recall of two blood pressure pills over cancer risk
FDA recalls two blood pressure pills due to risk that they may cause cancer
US pharmacies agree to $10bn opioid litigation settlement
US pharmacies agree to paying $10bn in opioid litigation settlement following opioid crisis
Potentially cancer-stopping pill given to first patient
New pill which may halt cancer is given to first patient in a trial
Cancer vaccine may be available by 2030
New cancer vaccine may be available by 2030
AI and digital tech open up new frontiers in neurology research
New digital technology and AI can further neurological research and clinical trials
Unmet needs in clinical tr ials for neurological conditions
Clinical trials in neurological conditions such as MS have been impacted by COVID-19, but how can they improve in the future?
The importance of treating TBIs early
Vasopharm tells Pharmafile about the significance of TBIs and the need to treat them in the acute phase
Looking to the future of neurology
Pharmafile speaks to UCB: UCB discuss the challenges facing neurology and how these can be overcome
Helping rare diseases emerge from the shadows to take centre stage
The rare disease treatment market has been rapidly changing and receive deserved recognition
Pharmarole
#Pharmarole coming soon!
The changing landscape of rare disease research
Pharmafile speaks to Chiesi Group: Chiesi Group tells Pharmafile about the challenges facing rare disease research and their hopes for the future of this area
The power of partnership: Collaborating with PAOs for better clinical research
Patient advocacy organisations can form an effective partnership between clinical trials and patients for more efficient trials
Rising to the unique challenges of rare diseases
Aaron Bean at Veeva explores the challenges of rare diseases: With up to 30 million people in EU living with rare diseases, Veeva discusses the challenges facing these rare diseases
Addressing inequalities in access to medicines in a post-COVID world
The challenge of cardiovascular disease: Daiichi Sankyo tells Pharmafile about their role in improving access to cardiovascular treatments and the prevention of CVD
Diuretic-resistant congestion– The road less travelled in novel treatments for chronic heart failure
What treatments can be used for diuretic-resistant congestion in chronic heart failure, and what challenges face them?
How RNA-based therapeutics improve care and benefit patients
Patients can benefit from new RNA-based therapeutics for metabolic care
Pharmafile EVENTS
Pharmafile Events 2022-2023
Innovations in Pharmaceutical Technology
Introducing the new Innovations in Pharmaceutical Technology website
PharmaTimes
PharmaTimes International Clinical Researcher of the Year
Pharmafile
Therapeutic areas in focus